Evidence map›Paper›PMID 38961245›Full record

ArticleCommunications biology2024

Mammalian cell display with automated oligo design and library assembly allows for rapid residue level conformational epitope mapping.

Niklas Berndt Thalén, Maximilian Karlander, Magnus Lundqvist, Helena Persson, Camilla Hofström, S Pauliina Turunen, Magdalena Godzwon, Anna-Luisa Volk, Magdalena Malm, Mats Ohlin and 1 more

Abstract read
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Niklas Berndt Thalén *Department Protein science, KTH-Royal Institute of Technology, Stockholm, SE-106 91, Sweden.
Maximilian Karlander *Department Protein science, KTH-Royal Institute of Technology, Stockholm, SE-106 91, Sweden.ORCID 0000-0001-7679-2145
Magnus LundqvistDepartment Protein science, KTH-Royal Institute of Technology, Stockholm, SE-106 91, Sweden.
Helena PerssonScience for Life Laboratory, Drug Discovery and Development Platform & School of Biotechnology, KTH-Royal Institute of Technology, Stockholm, Sweden.
Camilla HofströmScience for Life Laboratory, Drug Discovery and Development Platform & School of Biotechnology, KTH-Royal Institute of Technology, Stockholm, Sweden.
S Pauliina TurunenScience for Life Laboratory, Drug Discovery and Development Platform & School of Biotechnology, KTH-Royal Institute of Technology, Stockholm, Sweden.ORCID 0000-0001-8060-9876
Magdalena GodzwonDepartment of Immunotechnology, Lund University, Lund, Sweden.
Anna-Luisa VolkDepartment Protein science, KTH-Royal Institute of Technology, Stockholm, SE-106 91, Sweden.ORCID 0000-0003-1096-9061
Magdalena MalmDepartment Protein science, KTH-Royal Institute of Technology, Stockholm, SE-106 91, Sweden.ORCID 0000-0003-1763-9073
Mats OhlinDepartment of Immunotechnology, Lund University, Lund, Sweden.ORCID 0000-0002-5105-1938
Johan RockbergDepartment Protein science, KTH-Royal Institute of Technology, Stockholm, SE-106 91, Sweden. johanr@biotech.kth.se.ORCID 0000-0002-9977-5724

Funding

Stiftelsen för Strategisk Forskning (Swedish Foundation for Strategic Research) SB16-0017VINNOVA (Swedish Governmental Agency for Innovation Systems) 2016-05181VINNOVA (Swedish Governmental Agency for Innovation Systems) 2017-02105VINNOVA (Swedish Governmental Agency for Innovation Systems) 2019-00103VINNOVA (Swedish Governmental Agency for Innovation Systems) 2021-02640
6 · The paper itself

Abstract

Precise epitope determination of therapeutic antibodies is of great value as it allows for further comprehension of mechanism of action, therapeutic responsiveness prediction, avoidance of unwanted cross reactivity, and vaccine design. The golden standard for discontinuous epitope determination is the laborious X-ray crystallography method. Here, we present a combinatorial method for rapid mapping of discontinuous epitopes by mammalian antigen display, eliminating the need for protein expression and purification. The method is facilitated by automated workflows and tailored software for antigen analysis and oligonucleotide design. These oligos are used in automated mutagenesis to generate an antigen receptor library displayed on mammalian cells for direct binding analysis by flow cytometry. Through automated analysis of 33930 primers an optimized single condition cloning reaction was defined allowing for mutation of all surface-exposed residues of the receptor binding domain of SARS-CoV-2. All variants were functionally expressed, and two reference binders validated the method. Furthermore, epitopes of three novel therapeutic antibodies were successfully determined followed by evaluation of binding also towards SARS-CoV-2 Omicron BA.2. We find the method to be highly relevant for rapid construction of antigen libraries and determination of antibody epitopes, especially for the development of therapeutic interventions against novel pathogens.

Indexed as

COVID-19Epitope MappingEpitopesSARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsAntibodies, ViralCell Surface Display TechniquesGene LibraryHEK293 CellsHumansPeptide LibraryAntibodies, ViralEpitopesPeptide LibrarySpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID38961245
PMCPMC11222437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.